177Lu and 227Th Labeled 3,4,3-(LI-1,2-HOPO): characterization, optimized synthesis, biological distribution and dosimetry

• Published in: Nuclear medicine and biology Vol. 114-115; pp. S25 - S26
• Main Authors: Sanders, Vanessa, Phipps, Michael, Demoin, Dustin, Pratt, Edwin, Bhupathiraju, N.V.S. Dinesh, Ponnala, Shashikanth, Ferdous, Jannatul, Schlyer, David, Carter, Lukas, Lewis, Jason, Deri, Melissa, Cutler, Cathy, Francesconi, Lynn
• Format: Journal Article
• Language: English
• Published: United States Elsevier 08.12.2022
• Subjects: RADIOLOGY AND NUCLEAR MEDICINE
• ISSN: 0969-8051; 1872-9614
• DOI: 10.1016/S0969-8051(22)02144-8

Objectives: Interest in targeted radionuclide therapy has greatly increased namely due to the FDA approval of radiotherapeutic drugs such as Lutathera The identification of chelators that can bind diag- nostic and therapeutic radionuclides would allow facile development of agents tailored for personalized medicine. Hydroxypyridinonate (HOPO) derivatives have been demonstrated as effective decorpo- ration agents for actinides owing to their hard oxygen donor atoms and strong complexation. Utilizing these molecules as chelators for potential nuclear medicine agents should allow for radiometals to be effectively sequestered by the ligand. The aim of this work was to evaluate the in vivo stability of 3-4-3-(LI-1,2-HOPO) (HOPO for short) with 177Lu and 227Th as potential beta- and alpha-emitting radiothera- peutic complexes, respectively.